BiotechTube
Turing Medical

Turing Medical

San Francisco, United States· Est.
turingmedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

Turing Medical is a private, pre-revenue biotech firm founded in 2018, focusing on revolutionizing neuromodulation through AI and precision functional mapping. Its lead program is the PACE system, a non-invasive cortical stimulation therapy intended for severe depression and chronic pain, which is likely in pre-clinical or early clinical development. The company leverages its founders' seminal neuroscience research, published in journals like Nature, to build automated pipelines for brain targeting and also commercializes motion-reduction software (FIRMM) for improving MRI quality. Leadership includes a new CEO with medtech commercialization experience and a scientifically distinguished founding team.

Severe DepressionChronic Pain

Technology Platform

Precision functional brain mapping platform using advanced fMRI and AI to create individualized brain network maps for targeted neuromodulation. Includes FIRMM software for real-time MRI motion monitoring and correction.

Funding History

1
Total raised:$4.2M
Seed$4.2M

Opportunities

The large and growing global neuromodulation market for treatment-resistant depression and chronic pain presents a multi-billion dollar opportunity for a more effective, personalized therapy.
Additionally, the company's FIRMM software addresses a widespread problem in MRI diagnostics, creating a nearer-term revenue stream and establishing clinical utility for its core mapping technology.

Risk Factors

The company faces significant clinical risk in proving the safety and efficacy of its novel PACE therapy, as well as regulatory risk in navigating the FDA approval pathway for a new neuromodulation device.
As a pre-revenue private company, it also carries financing risk, requiring substantial capital to advance through costly clinical trials.

Competitive Landscape

Turing competes in the neuromodulation space against established players like Abbott, Boston Scientific, and Medtronic, as well as TMS providers (e.g., Neuronetics). Its differentiation lies in precision targeting based on individual functional connectivity, a approach also being explored by some research-stage neurotech firms. In MRI motion correction, it competes with various software and hardware solutions from imaging vendors and specialized software companies.

More companies in Neuroscience & CNS →More companies in United States →